ANI Pharmaceuticals Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
ANI Pharma (ANIP) Misses Q3 EPS by 20c, Revenues Miss; Offers FY19 EPS/Revenue Guidance Below Consensus
November 6, 2019 8:32 AM ESTANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.23, $0.20 worse than the analyst estimate of $1.43. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.97 million.
For the third quarter 2019:
Net revenues of $51.3 million, an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32Adjusted non-GAAP EBITDA of $19.8 million and... More